OM
PETX

Opaleye Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Opaleye Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-420,000
Closed -$2.57M – 48
2017
Q3 		$2.57M Buy
420,000
+69,800
+20% +$442K 0.91% 28
2017
Q2 		$2.28M Buy
+350,200
New +$2.15M 0.95% 28

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Opaleye Management's PETX Position: Q4 2017 in Review

Opaleye Management sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2017, closing a stake of 420,000 shares — an estimated $2.57M sold.

Opaleye Management first reported a position in PETX in Q2 2017 and held it in 2 quarters. The position peaked at $2.57M in Q3 2017. 105 funds tracked by Wall St. Rank hold PETX as of Q4 2017.

  • Opaleye Management reported no remaining Aratana Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Opaleye Management sold 420,000 Aratana Therapeutics, Inc. shares in Q4 2017, an estimated $2.57M.
  • Opaleye Management first reported a position in Aratana Therapeutics, Inc. in Q2 2017 and held it in 2 quarters.
  • Opaleye Management's Aratana Therapeutics, Inc. position peaked at $2.57M in Q3 2017.
  • 105 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2017.

Based on Opaleye Management's 13F filing for Q4 2017, filed 9 Feb 2018.